|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13,514.00 GBX | -0.57% |
|
-1.31% | +29.10% |
| 12-10 | Health Rounds: Regeneron drug wipes out residual multiple myeloma cells in small trial | RE |
| 12-10 | Banks support FTSE 100 ahead of Fed decision | RE |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||
Cash And Equivalents | 7.83B | 6.33B | 6.17B | 5.84B | 5.49B | |||||
Short Term Investments | 42M | 53M | 64M | - | - | |||||
Trading Asset Securities, Total | 161M | 16M | 14M | 20M | 37M | |||||
Total Cash And Short Term Investments | 8.04B | 6.4B | 6.24B | 5.86B | 5.52B | |||||
Accounts Receivable, Total | 3.81B | 6.03B | 7.21B | 8.41B | 8.3B | |||||
Other Receivables | 1.84B | 2.76B | 2.71B | 3.53B | 4.79B | |||||
Total Receivables | 5.65B | 8.8B | 9.92B | 11.94B | 13.09B | |||||
Inventory | 4.02B | 8.98B | 4.7B | 5.42B | 5.29B | |||||
Prepaid Expenses | 1.74B | 1.51B | 1.33B | 1.62B | 1.74B | |||||
Restricted Cash | - | - | 162M | 102M | 129M | |||||
Other Current Assets, Total | 99M | 556M | 236M | 116M | 54M | |||||
Total Current Assets | 19.54B | 26.24B | 22.59B | 25.05B | 25.83B | |||||
Gross Property Plant And Equipment | 17.11B | 18.5B | 17.19B | 19.1B | 20.52B | |||||
Accumulated Depreciation | -8.19B | -8.32B | -7.74B | -8.6B | -8.88B | |||||
Net Property Plant And Equipment | 8.92B | 10.17B | 9.45B | 10.5B | 11.65B | |||||
Long-term Investments | 1.19B | 1.26B | 1.14B | 1.68B | 1.9B | |||||
Goodwill | 11.84B | 20B | 19.82B | 20.05B | 21.02B | |||||
Other Intangibles, Total | 20.95B | 42.39B | 39.31B | 38.09B | 37.18B | |||||
Deferred Tax Assets Long-Term | 3.44B | 4.33B | 3.26B | 4.72B | 5.35B | |||||
Other Long-Term Assets, Total | 846M | 972M | 909M | 1.03B | 1.11B | |||||
Total Assets | 66.73B | 105B | 96.48B | 101B | 104B | |||||
Liabilities | ||||||||||
Accounts Payable, Total | 2.35B | 2.82B | 2.55B | 3.27B | 3.64B | |||||
Accrued Expenses, Total | 9.69B | 12.36B | 13.43B | 15.74B | 16.09B | |||||
Short-term Borrowings | 661M | 411M | 5.31B | 5.13B | 330M | |||||
Current Portion of Long-Term Debt | 1.57B | 2.25B | 960M | 989M | 2.06B | |||||
Current Portion of Leases | 192M | 233M | 228M | 271M | 339M | |||||
Current Income Taxes Payable | 1.13B | 916M | 896M | 1.58B | 1.41B | |||||
Unearned Revenue Current, Total | 1.96B | 1.18B | 269M | 251M | 126M | |||||
Other Current Liabilities | 2.76B | 2.42B | 2.65B | 3.31B | 3.88B | |||||
Total Current Liabilities | 20.31B | 22.59B | 26.29B | 30.54B | 27.87B | |||||
Long-Term Debt | 19.8B | 29.72B | 23.91B | 22.4B | 26.62B | |||||
Long-Term Leases | 489M | 754M | 725M | 857M | 1.11B | |||||
Unearned Revenue Non Current | 38M | 26M | 14M | 7M | - | |||||
Pension & Other Post Retirement Benefits | 3.2B | 2.45B | 1.17B | 1.52B | 1.33B | |||||
Deferred Tax Liability Non Current | 2.92B | 6.21B | 2.94B | 2.84B | 3.3B | |||||
Other Non Current Liabilities | 4.33B | 4.32B | 4.37B | 3.78B | 2.93B | |||||
Total Liabilities | 51.09B | 66.08B | 59.42B | 61.95B | 63.16B | |||||
Common Stock, Total | 328M | 387M | 387M | 388M | 388M | |||||
Additional Paid In Capital | 7.97B | 35.13B | 35.16B | 35.19B | 35.23B | |||||
Retained Earnings | 6.44B | 3.64B | 3.12B | 4.52B | 7.23B | |||||
Comprehensive Income and Other | 881M | 111M | -1.62B | -949M | -2.06B | |||||
Total Common Equity | 15.62B | 39.27B | 37.04B | 39.14B | 40.79B | |||||
Minority Interest | 16M | 19M | 21M | 23M | 85M | |||||
Total Equity | 15.64B | 39.29B | 37.06B | 39.17B | 40.87B | |||||
Total Liabilities And Equity | 66.73B | 105B | 96.48B | 101B | 104B | |||||
Supplemental Items | ||||||||||
ECS Total Shares Outstanding on Filing Date | 1.31B | 1.55B | 1.55B | 1.55B | 1.55B | |||||
ECS Total Common Shares Outstanding | 1.31B | 1.55B | 1.55B | 1.55B | 1.55B | |||||
Book Value / Share | 11.9 | 25.34 | 23.9 | 25.25 | 26.3 | |||||
Tangible Book Value | -17.17B | -23.12B | -22.09B | -18.99B | -17.42B | |||||
Tangible Book Value Per Share | -13.08 | -14.92 | -14.25 | -12.25 | -11.23 | |||||
Total Debt | 22.71B | 33.36B | 31.14B | 29.65B | 30.46B | |||||
Net Debt | 14.68B | 26.96B | 24.89B | 23.79B | 24.94B | |||||
Debt Equivalent of Unfunded Proj. Benefit Obligation | 3.23B | 2.5B | 1.12B | 1.48B | 1.27B | |||||
Debt Equivalent Oper. Leases | -32M | 48M | - | - | - | |||||
Minority Interest, Total (Incl. Fin. Div) | 16M | 19M | 21M | 23M | 85M | |||||
Equity Method Investments, Total | 39M | 69M | 76M | 147M | 268M | |||||
Account Code - Inventory Valuation | 3 | 3 | 3 | 3 | 3 | |||||
Inventories - Raw Materials, Total | 1.26B | 1.76B | 1.42B | 1.53B | 1.49B | |||||
Inventories - Work In Process, Total | 1.33B | 5.22B | 1.86B | 2.32B | 2.28B | |||||
Inventories - Finished Goods, Total | 1.43B | 2.01B | 1.41B | 1.57B | 1.52B | |||||
Land - (BS) | 5.85B | 6.38B | 5.44B | 6.47B | 6.58B | |||||
Machinery, Total | 7.74B | 7.9B | 7.56B | 8.7B | 8.85B | |||||
Full Time Employees | 76.1K | 83.1K | 83.5K | 89.9K | 94.3K | |||||
Accumulated Allowance for Doubtful Accounts (Supple) | 23M | 23M | 59M | 45M | 33M |
- Stock Market
- Equities
- AZN Stock
- Financials AstraZeneca PLC
- Balance Sheet
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















